Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Closed 10-19 16:00:00 EDT

36.64

+0.86

+2.40%

盘后36.64

+0.000.00%

19:52 EDT

High36.79	Low35.64	Vol831.53K
Open36.00	D1 Closing35.78	Amplitude3.23%
Mkt Cap1.25B	Tradable Cap1.23B	Total Shares34.14M
T/O30.30M	T/O Rate2.48%	Tradable Shares33.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":36.64,"timestamp":1792440000000,"preClose":35.78,"halted":0,"volume":831532,"hourTrading":{"tag":"盘后","latestPrice":36.64,"preClose":36.64,"latestTime":"19:52 EDT","volume":36758,"amount":1346812.99,"timestamp":1792453953512,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02403577417551703,"floatShares":33545280,"shares":34142994,"eps":-6.468026,"marketStatus":"Closed","change":0.86,"latestTime":"10-19 16:00:00 EDT","open":36,"high":36.79,"low":35.635,"amount":30298940.597744,"amplitude":0.032281,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.468026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792483200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":35.78,"preHourTrading":{"tag":"盘前","latestPrice":36.03,"preClose":35.78,"latestTime":"09:29 EDT","volume":8174,"amount":295301.44408,"timestamp":1792416599999,"change":0.25,"changeRate":0.006987,"amplitude":0.081051},"postHourTrading":{"tag":"盘后","latestPrice":36.64,"preClose":36.64,"latestTime":"19:52 EDT","volume":36758,"amount":1346812.99,"timestamp":1792453953512,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.74726,"impliedVol":0.7979,"impliedVolPercentile":0.5179},"requestUrl":"/m/hq/s/NKTR/wiki","defaultTab":"wiki","newsList":[{"id":"2674446803","title":"Nektar Therapeutics Initiated at Neutral by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2674446803","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674446803?lang=en_us&edition=fundamental","pubTime":"2026-10-12 22:00","pubTimestamp":1791813600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674966872","title":"UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674966872","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674966872?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:38","pubTimestamp":1791805096,"startTime":"0","endTime":"0","summary":"UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674879609","title":"Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2674879609","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674879609?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:14","pubTimestamp":1791800068,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) has an average rating of buy and mean price target of $141.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELS","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674841786","title":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674841786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674841786?lang=en_us&edition=fundamental","pubTime":"2026-10-12 07:01","pubTimestamp":1791759679,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM) and Nektar Therapeutics (NKTR) with bu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-insmed-insm-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INSM","XLV","LU0109394709.USD","BK4581","LU0128526141.USD","NKTR","HCSG","BK4007","BK4588","LU0029874061.USD","BK4139","LU0053671581.USD","LU0889565916.HKD","BK4137","XBI","BK4585","LU0320765992.SGD","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674685697","title":"Nektar Therapeutics Initiated at Market Perform by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674685697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674685697?lang=en_us&edition=fundamental","pubTime":"2026-10-09 19:09","pubTimestamp":1791544140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","BK4007","IE00B3QW5Z07.USD","LU1363072403.SGD","IE00BGHQF748.EUR","LU0971096721.USD","LU2265009873.SGD","NKTR","IE00B64PRP62.GBP","RJF","BK4139","LU1804176565.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674343048","title":"Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674343048","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674343048?lang=en_us&edition=fundamental","pubTime":"2026-10-09 14:45","pubTimestamp":1791528314,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics reported past long term Phase 2b data for rezpegaldesleukin in alopecia areata and atopic dermatitis, along with a $115 million legal win over Eli Lilly that removes a long running contract dispute overhang.\nThe same rezpegaldesleukin data set highlights durable responses with less frequent dosing schedules, which directly affects future trial design, treatment positioning, and potential development costs.\nWe will now look at how Nektar Therapeutics' investment narrative...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/lawsuit-win-could-be-a-game-changer-for-nektar-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674100059","title":"Nektar initiated with a Market Perform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674100059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674100059?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:10","pubTimestamp":1791490246,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Nektar (NKTR) with a Market Perform rating and no price target Treg modulation is “a scientifically compelling ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-initiated-with-a-market-perform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IE00B3QW5Z07.USD","RJF","LU2265009873.SGD","NKTR","LU1804176565.USD","BK4127","LU0971096721.USD","BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","LU1363072403.SGD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672671402","title":"B. Riley Securities Keeps Their Buy Rating on Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2672671402","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672671402?lang=en_us&edition=fundamental","pubTime":"2026-10-02 20:55","pubTimestamp":1790945729,"startTime":"0","endTime":"0","summary":"In a report released today, from B. Riley Securities maintained a Buy rating on Nektar Therapeutics, with a price target of $150.00. In addition to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/b-riley-securities-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/b-riley-securities-keeps-their-buy-rating-on-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672719074","title":"Nektar Therapeutics Price Target Maintained with a $185.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2672719074","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672719074?lang=en_us&edition=fundamental","pubTime":"2026-10-02 19:39","pubTimestamp":1790941140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672168177","title":"Nektar selloff yesterday overdone, says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2672168177","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672168177?lang=en_us&edition=fundamental","pubTime":"2026-10-02 18:15","pubTimestamp":1790936148,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He views the 22% pullback yesterday in shares of Nektar (NKTR) as overdone. The company presented 52-week treatment ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-selloff-yesterday-overdone-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-selloff-yesterday-overdone-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162160441","title":"Movement Alert｜Nektar Therapeutics Falls 19.63% in Regular Trading, Trading at $48.81","url":"https://stock-news.laohu8.com/highlight/detail?id=1162160441","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162160441?lang=en_us&edition=fundamental","pubTime":"2026-10-02 02:41","pubTimestamp":1790880064,"startTime":"0","endTime":"0","summary":"On October 1, Nektar Therapeutics fell 19.63% in regular trading, trading at $48.81 USD/share, with Turnover of $206 million.Within the Pharmacy sector where Nektar Therapeutics belongs, individual...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672323761","title":"Nektar selloff after rezpegaldesleukin data ‘unwarranted,’ says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2672323761","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672323761?lang=en_us&edition=fundamental","pubTime":"2026-10-02 02:25","pubTimestamp":1790879111,"startTime":"0","endTime":"0","summary":"Jefferies analyst Roger Song sees the selloff in shares of Nektar (NKTR) following updated rezpegaldesleukin data “unwarranted.” The off-treatment ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-selloff-after-rezpegaldesleukin-data-unwarranted-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-selloff-after-rezpegaldesleukin-data-unwarranted-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672766371","title":"William Blair says rezpeg data a positive for Nektar","url":"https://stock-news.laohu8.com/highlight/detail?id=2672766371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672766371?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:15","pubTimestamp":1790871334,"startTime":"0","endTime":"0","summary":"William Blair analyst Andy Hsieh maintained an Outperform rating on Nektar (NKTR) Therapeutics following updated rezpegaldesleukin, or rezpeg, data...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/william-blair-says-rezpeg-data-a-positive-for-nektar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/william-blair-says-rezpeg-data-a-positive-for-nektar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672876509","title":"Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023","url":"https://stock-news.laohu8.com/highlight/detail?id=2672876509","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672876509?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:12","pubTimestamp":1790871120,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics  is currently at $47.86, down $12.68 or 20.94%--Would be lowest close since Feb. 9, 2026, when it closed at $37.07--On pace for largest percent decrease since Feb. 24, 2023, when it fell 49.66%--Currently down three of the past five days--Up 13.21% year-to-date--Down 97.06% from its all-time closing high of $1626.60 on March 8, 2018--Down 20.88% from 52 weeks ago , when it closed at $60.50--Down 52.3% from its 52-week closing high of $100.35 on April 20, 2026--Up 36.29% from its 52-week closing low of $35.12 on Feb. 5, 2026--Traded as low as $47.15; lowest intraday level since Feb. 10, 2026, when it hit $47.05--Down 22.12% at today's intraday low; largest intraday percent decrease since Feb. 24, 2023, when it fell as much as 50.68%All data as of 12:09:43 PM ETSource: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ISHG","BBLB","BK4585","TBJL","FLGV","BWX","SHY","BBSB","TLT","TLH","TLTX","BWZ","HMOP","IEI","BBIB","IGOV","TLTI","SGOV","TFJL","BK4588","NKTR","IEF","BK4007","SHV","TLTW","TSYW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672766847","title":"Nektar falls -21.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2672766847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672766847?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:05","pubTimestamp":1790870744,"startTime":"0","endTime":"0","summary":"Nektar (NKTR) is down -21.6%, or -$13.09 to $47.46. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-falls-21-6-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-falls-21-6-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672176561","title":"Nektar Stock Sinks Despite Promising Hair Loss Treatment Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2672176561","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672176561?lang=en_us&edition=fundamental","pubTime":"2026-10-01 23:45","pubTimestamp":1790869500,"startTime":"0","endTime":"0","summary":"Shares of Nektar Therapeutics sank on Thursday despite promising long-term trial data for its experimental treatment for alopecia areata, a chronic autoimmune disease that causes hair loss.Nektar stoc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QTTB","NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672723751","title":"Nektar Says Phase 3 Zenith AD Trial for Rezpegaldesleukin Expands into Treatment-Experienced Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2672723751","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672723751?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:31","pubTimestamp":1790854295,"startTime":"0","endTime":"0","summary":"Nektar says Phase 3 ZENITH AD trial for rezpegaldesleukin expands into treatment-experienced patientsNektar Therapeutics presented 1-year Phase 2b data for rezpegaldesleukin at EADV Congress 2026 in V","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL24lQRj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751229","title":"Nektar Therapeutics - Rezpegaldesleukin Demonstrates Durability and Deepening of Response Through One Year of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751229?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:30","pubTimestamp":1790854206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751218","title":"Nektar Therapeutics - Rezpegaldesleukin Safety Profile Through 52 Weeks Favorable and Consistent with Previous Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751218","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751218?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:30","pubTimestamp":1790854206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N088:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672219751","title":"Nektar Therapeutics - Phase 3 Zenith Aa Study to Initiate in Early 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2672219751","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672219751?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:30","pubTimestamp":1790854206,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nFWN45N088:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.1309},{"period":"1month","weight":-0.469},{"period":"3month","weight":-0.4758},{"period":"6month","weight":-0.5784},{"period":"1year","weight":-0.349},{"period":"ytd","weight":-0.1537}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.018591},{"month":8,"riseRate":0.484848,"avgChangeRate":0.043831},{"month":9,"riseRate":0.484848,"avgChangeRate":0.036592},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.034977},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}